Amendments to Bylaws (Form 8-K)

On April 3, 2025, based on the recommendation of the nominating and corporate governance committee of the board of directors (the "Board") of Intellia Therapeutics, Inc. (the "Company"), the Board adopted and approved the amendment and restatement of the Company's Second Amended and Restated By-lawsin their entirety, effective as of April 3, 2025. The Third Amended and Restated By-laws(the "Amended By-laws")include, among other things, the following changes: (1) adopting a majority vote standard in uncontested elections for director positions, while retaining a plurality vote standard in contested elections in which the number of director candidates exceeds the number of directors to be elected; (2) implementing proxy solicitation procedures consistent with Rule 14a-19of the Securities Exchange Act of 1934, as amended; and (3) making certain other clarifying and procedural changes.

A copy of the Amended By-lawsis filed as Exhibit 3.1 to this Current Report on Form 8-K andis incorporated herein by reference, and the foregoing summary is qualified in its entirety by reference to the full text of the Amended By-laws.